The Trulicity Experience

Real patients. Real stories.

Hear from actual Trulicity patients on how Trulicity has impacted the way they manage their type 2 diabetes.

In addition to glycemic control, could the Trulicity experience give your patients the motivation they need to start and stay on a new treatment?*1-6

Icon of calendar

Once weekly

Icon of the Trulicity Pen

Pen that patients preferred

Icon of scale

Possible weight loss

*In a study, 97% of injection-naïve patients were willing to continue using the Trulicity Pen. The primary objective of a success rate significantly greater than 80% at the fourth weekly injection was met. 99.1% [95% CI: 96.6% to 99.7%] (n=209) of patients successfully completed each step in the sequence of drug administration after proper self-injection training at baseline. Limitations include the administration of placebo rather than active drug product. After the final self-injection, patients completed an 8-item experience module (secondary endpoint). 203 (96.7%) out of 210 patients reported that they were "mostly willing" or "definitely willing" to continue using the single-dose pen.6

In a patient preference study between the Trulicity Pen and the Ozempic pen.8 For study results and description, click here.

  • Open-label, multicenter, randomized, crossover study to evaluate patient preference between the Trulicity Pen and the Ozempic pen among adults with type 2 diabetes who were naïve to self-injecting and injecting others (N=310). Primary outcome: Difference in preference between two devices measured by global preference item “Overall which device do you prefer?”
  • These data make no representation or conclusion as to the factors contributing to patient preference. These data do not establish clinical comparability of the products for any indications and should not be seen as making any claim regarding efficacy and safety.
  • Limitations include the use of injection pads rather than actual injections.

Trulicity is not indicated for weight loss.

In clinical studies, weight change was a secondary endpoint. Mean weight change was -1.1 lb to -6.8 lb at the 1.5 mg dose and +0.4 lb to -6.0 lb at the 0.75 mg dose.1,7

What would help patients be more willing and able to administer treatment once they leave the office?

Trulicity offers adult patients with type 2 diabetes1,2:
No fasting
No waiting to eat
No attaching a needle
No priming


Preparation2

  • Check the pen to be sure it is not expired or damaged and that the medicine is not cloudy, discolored, or has particles in it
  • Choose an area for injection (abdomen or thigh), being sure to choose a different site (even within an area) each week

Key administration steps2

1
Uncap the pen
2
Place and unlock
3
Press and hold

Disposal2

  • Dispose of the pen in a closable puncture-resistant container and not in household trash

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Trulicity.

Can a simple administration experience help patients continue on your treatment plan?

[Bubbles with 99%, 98%, 99% with 97%]

Patients preferred the Trulicity Pen over the Ozempic pen8

[Pie chart showing 84% of patients preferred the Trulicity Pen, 12% preferred the Ozempic device, and 4% had no preference]

These data make no representation or conclusion as to the factors contributing to patient preference.
These data do not establish clinical comparability of the products for any indications and should not be seen as making any claim regarding efficacy and safety.

Limitations of the study include the use of injection pads rather than actual injections and the participants only used each device one time.

 


More patients were willing to use the Trulicity Pen8

More than twice as many patients were willing to use the Trulicity Pen than the Ozempic pen after being trained on the devices8

[Chart showing more patients were willing to use the Trulicity Pen]

The patients were trained from the start of training, with time to ask questions, until successful completion of and injection into an injection pad.

These data make no representation or conclusion as to the factors contributing to patient preference.
These data do not establish clinical comparability of the products for any indications and should not be seen as making any claim regarding efficacy or safety.

Study Descriptions

Investigation of the safe and effective use of the Trulicity Pen6

  • Phase 3b, multicenter, single-arm, outpatient study on the safe and effective use of the Trulicity single-dose pen in patients with type 2 diabetes who were naïve to self-injection and injecting others (n=214)
  • The primary objective of a success rate significantly greater than 80% at the fourth weekly injection was met. 99.1% [95% CI: 96.6% to 99.7%] (n=209) of patients successfully completed each step in the sequence of drug administration after proper self-injection training at baseline
  • Limitations include the administration of placebo rather than active drug product and the willingness of injection-naïve patients to self-inject, which may not be entirely representative of an injection-naïve type 2 diabetes patient population. The patients in this study with fairly well-controlled type 2 diabetes may not be entirely representative of an injection-naïve population progressing to injectable therapy. In clinical practice, patient training on self-injection with the single-dose pen may differ from the method in this study
  • After the final self-injection, patients completed a 12-item ease-of-use module (secondary endpoint). 208 (99%) out of 210 patients reported that overall, the single-dose pen was “easy” or “very easy” to use
  • After the final self-injection, patients completed an 8-item experience module (secondary endpoint). 206 (98.1%) out of 210 patients “agreed” or “strongly agreed” that it was convenient to take injections with the single-dose pen
  • After the final self-injection, patients completed an 8-item experience module (secondary endpoint). 203 (96.7%) out of 210 patients reported that they were “mostly willing” or “definitely willing” to continue using the single-dose pen

Pen preference compared to Ozempic8

  • Open‐label, multicenter, randomized, crossover study to evaluate patient preference between the Trulicity Pen and the Ozempic pen among adults with type 2 diabetes who were naïve to self‐injecting and injecting others (N=310)
  • Patients read and were trained on the Instructions for Use for each device containing the lowest available dose of medication prior to administering mock injections into an injection pad. After using both devices, patients reported which device they preferred (primary endpoint) and completed a 10‐item preference questionnaire. Patients completed questions on willingness to use before device trainings and after using the devices
  • Primary outcome: Difference in preference between two devices measured by global preference item “Overall which device do you prefer”
  • Limitations include the use of injection pads rather than actual injections and the participants used each device only one time
  • Exploratory objective: Patients responded to supplemental questions on willingness to use the device in administered survey
  • Exploratory objective: Time to train was assessed on a subset of patients (N=78). The patients were timed from the start of training, with time to ask questions, until successful completion of an injection into an injection pad

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top